Epirus Biopharmaceuticals Stock Fundamentals
| EPRSQDelisted Stock | USD 0.0001 0.00 0.00% |
EPIRUS Biopharmaceuticals fundamentals help investors to digest information that contributes to EPIRUS Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of EPIRUS Pink Sheet. The fundamental analysis module provides a way to measure EPIRUS Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to EPIRUS Biopharmaceutica pink sheet.
EPIRUS |
EPIRUS Biopharmaceuticals Company Current Valuation Analysis
EPIRUS Biopharmaceutica's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current EPIRUS Biopharmaceutica Current Valuation | (6 M) |
Most of EPIRUS Biopharmaceutica's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, EPIRUS Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, EPIRUS Biopharmaceuticals has a Current Valuation of (6 Million). This is 100.04% lower than that of the Biotechnology sector and 100.13% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.04% higher than that of the company.
EPIRUS Biopharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining EPIRUS Biopharmaceutica's current stock value. Our valuation model uses many indicators to compare EPIRUS Biopharmaceutica value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across EPIRUS Biopharmaceutica competition to find correlations between indicators driving EPIRUS Biopharmaceutica's intrinsic value. More Info.EPIRUS Biopharmaceuticals is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the EPIRUS Biopharmaceutica's earnings, one of the primary drivers of an investment's value.EPIRUS Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses EPIRUS Biopharmaceutica's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of EPIRUS Biopharmaceutica could also be used in its relative valuation, which is a method of valuing EPIRUS Biopharmaceutica by comparing valuation metrics of similar companies.EPIRUS Biopharmaceutica is currently under evaluation in current valuation category among its peers.
EPIRUS Fundamentals
| Return On Equity | -1.22 | |||
| Return On Asset | -0.45 | |||
| Operating Margin | (37.45) % | |||
| Current Valuation | (6 M) | |||
| Shares Outstanding | 26.18 M | |||
| Number Of Shares Shorted | 252.54 K | |||
| Price To Earning | (0.01) X | |||
| Price To Book | 0 X | |||
| Price To Sales | 0.0001 X | |||
| Revenue | 701 K | |||
| Gross Profit | 576 K | |||
| EBITDA | (54.6 M) | |||
| Net Income | (52.19 M) | |||
| Cash And Equivalents | 20.86 M | |||
| Cash Per Share | 0.80 X | |||
| Total Debt | 14.85 M | |||
| Debt To Equity | 0.57 % | |||
| Current Ratio | 0.79 X | |||
| Book Value Per Share | 1.00 X | |||
| Cash Flow From Operations | (46.58 M) | |||
| Short Ratio | 0.07 X | |||
| Earnings Per Share | (2.52) X | |||
| Target Price | 2.0 | |||
| Number Of Employees | 73 | |||
| Beta | 4.28 | |||
| Market Capitalization | 157 | |||
| Total Asset | 72.26 M | |||
| Retained Earnings | (155.03 M) | |||
| Working Capital | (6.93 M) | |||
| Current Asset | 25.69 M | |||
| Current Liabilities | 32.63 M | |||
| Z Score | -2.8 | |||
| Net Asset | 72.26 M |
About EPIRUS Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze EPIRUS Biopharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of EPIRUS Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of EPIRUS Biopharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts. EPIRUS BIOPHARMACEUTICA operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs 73 people.
Pair Trading with EPIRUS Biopharmaceutica
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if EPIRUS Biopharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EPIRUS Biopharmaceutica will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to EPIRUS Biopharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace EPIRUS Biopharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back EPIRUS Biopharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling EPIRUS Biopharmaceuticals to buy it.
The correlation of EPIRUS Biopharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as EPIRUS Biopharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if EPIRUS Biopharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for EPIRUS Biopharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in EPIRUS Pink Sheet
If you are still planning to invest in EPIRUS Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EPIRUS Biopharmaceutica's history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |